JCJordan Cates

Jordan Cates

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jordan Cates has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of Rotavirus Vaccine Effectiveness by Severity of Rotavirus Disease: Findings From the MNSSTER-V Project

    by Mary C. Moran, Jordan Cates, Neha Balachandran, Jazmina Umana, Helah Safi, Hammarskjold Makhuza, Volga Iniguez, Nguyen Van Trang, Isidore Bonkoungou, Cissy Nalunkuma, et al.

    Background: Since the introduction of rotavirus vaccines, acute gastroenteritis (AGE) hospitalizations due to rotavirus have decreased globally; however, vaccine effectiveness (VE) differs by country, age and disease severity. We evaluated rotavirus VE by disease severity in different age groups and under-5 childhood mortality (U5M) strata. Methods: The Vesikari score is a common measure of AGE disease severity. A modified Vesikari Score (mVS) was calculated for 18,426 children with medically attended AGE across 16 countries from the Multi-National Subpopulations Study To Evaluate Rotavirus Vaccines dataset. Using a test-negative case–control design (cases had rotavirus-positive AGE and controls had rotavirus-negative AGE), we calculated complete rotavirus series VE against different severity categories among children 6–59 months old, stratified by age and country U5M level, respectively. Results: VE increased with increasing disease severity: 38% (95% confidence interval [CI]:17–53) for mild/moderate disease versus 58% (95% CI: 50–64) for severe/very severe disease, and this pattern persisted with stratification by age and U5M. Among children with severe/very severe disease, VE was higher in infants 6–11 months (62%, 95% CI: 51–70) compared with children 24–59 months old (11%, 95% CI: −78 to 56), and lower among children in the highest U5M strata (44%, 95% CI: 26–58) compared to children in the high U5M strata (60%, 95% CI: 47–69). Conclusions: Rotavirus vaccines provide the greatest protection against very severe rotavirus disease. VE remains lower in countries with higher U5M levels, even among children with very severe rotavirus disease, highlighting the need for improved vaccine performance in countries with high disease burden.


  • Role of Vaccine Age Restrictions on Rotavirus Vaccine Coverage, Vaccine Safety Datalink 2018-2024

    by Jordan E Cates, Jacob Haapala, Julia M Baker, Gabriela Vazquez-Benitez, Matthew F Daley, Bruno Lewin, Nicola P Klein, Allison L Naleway, Lisa A Jackson, Joshua T B Williams, et al.

    Background: Rotavirus vaccines (RVs) are coadministered in the United States with diphtheria–tetanus–acellular pertussis (DTaP) vaccines but have age restrictions for the first and last doses. We examined how delays in preventive care visits for vaccination affected RV initiation and series completion. Methods: We compared the timeliness of DTaP vaccination relative to RV in children born January 1, 2018 to June 30, 2023 across 8 US health systems. Adjusted risk ratios (aRRs) were estimated using modified Poisson regression to identify risk factors for delayed DTaP vaccination and no RV vaccination. Results: Among 391 892 children who initiated DTaP, 12 546 (3.2%) did not initiate RV. Of these, 7721 (61.5%) children had delayed DTaP initiation and were age-ineligible for RV at the time of DTaP initiation. Children who became eligible for RV during the early stage of the COVID-19 pandemic (March to May 2020) had a higher risk of delayed DTaP and no RV initiation (aRR = 2.20; 95% CI, 1.98-2.45), as did children with fewer than 5 primary care visits within the first year of life (aRR = 4.03; 95% CI, 3.81-4.26), and Medicaid recipients (aRR = 2.34; 95% CI, 2.23-2.45). Similar factors were associated with failure to complete the RV series due to age restrictions. Conclusions: Age restrictions may have contributed to lack of RV initiation and series completion in this cohort. Public health strategies tailored to populations at risk for delayed vaccination may be needed to promote timely administration of RV.

  • Open Access

    Health Care Costs Associated With Norovirus at the Veterans Health Administration

    by Jordan E. Cates, Richard E. Nelson, Ying Suo, Umesh D. Parashar, Cynthia A. Lucero-Obusan, Mark Holodniy, Sara A. Mirza

    Importance: Norovirus is the leading cause of acute gastroenteritis among all ages in the US. Older adults, including veterans, are a potential target group for future vaccination and therapeutics, and more data are needed on the economic burden of norovirus among this population.Objective: To quantify the outpatient, emergency department (ED), and inpatient health care costs associated with laboratory-confirmed norovirus episodes among veterans seeking care in the Veterans Health Administration (VHA).Design, Setting, and Participants: This economic evaluation used VHA electronic health record and health care cost data between January 1, 2010, and December 31, 2024, with costs adjusted to 2024 dollars. Participants were veterans (aged ≥18 years) with norovirus who sought care from VHA clinics and hospitals nationwide. Norovirus episodes were categorized as outpatient, ED, or inpatient.Exposure: Norovirus episodes laboratory-confirmed by polymerase chain reaction assays.Main Outcomes and Measures: Outpatient, ED, and inpatient costs for encounters or admissions within 2 days of the norovirus-positive test result. Costs were extrapolated to the expected number of annual norovirus episodes with and without laboratory confirmation in the VHA using published incidence rates.Results: A total of 7768 norovirus episodes from 7520 patients (median [IQR] age, 62 [45-74] years; 6862 males [88%]; median [IQR] Charlson Comorbidity Index [CCI], 1 [0-4]) were included in the analysis. There were 3520 outpatient, 2018 ED, and 2230 inpatient norovirus episodes, with respective median (IQR) costs of $640 ($207-$1291), $2203 ($1596-$2989), and $14 083 ($8045-$26 672). Median (IQR) inpatient costs were higher among older age groups ($12 777 [$7297-$23 737], $16 075 [$9291-$29 311], and $18 566 [$10 676-$33 582] for those aged 45-64 years, 65-84 years, and ≥85 years, respectively) than younger adults ($7751 [$4768-$14 984] and $9394 [$5474-$15 830] for those aged 18-24 years and 25-44 years, respectively; P < .001). Median (IQR) inpatient costs were also higher across CCI categories, with the highest for CCI of 5 or higher ($18 508 [$10 445-$35 900]). The overall extrapolated annual cost to the VHA was $28 438 556.Conclusions and Relevance: This study found norovirus to be a substantial economic burden in the VHA. Developing targeted interventions, such as vaccines and antivirals, for this population may result in cost savings.

  • Indirect protection from rotavirus vaccines: a systematic review

    by Tyler Chavers, Jordan Cates, Eleanor Burnett, Umesh D. Parashar, Jacqueline E. Tate

    Rotavirus vaccines may provide indirect protection by reducing transmission in the population and thus reducing disease burden. This systematic review summarizes estimates of indirect protection from rotavirus vaccines and the methods used to obtain these estimates. We identified 71 studies published between 2009 and 2022 that provided 399 estimates of indirect protection from rotavirus vaccine. Most estimates (73%) evaluated hospitalizations due to rotavirus gastroenteritis as the outcome and unvaccinated children n = 110 estimates), the median relative percent change in percent positivity was 25% (IQR: 13-44%, n = 49 estimates), and the median relative percent change in absolute number of rotavirus positive tests or rotavirus-specific International Classification of Diseases codes was 42% (IQR: 16-66%, n = 40 estimates). These findings broadly suggest rotavirus vaccines provide some indirect protection. There is a need to standardize measurement of indirect rotavirus vaccine protection, particularly using consistent outcomes and metrics, and stratifying results by standardized age groups and years since vaccine introduction.


  • Open Access

    Clinical Severity of Enteric Viruses Detected Using a Quantitative Molecular Assay Compared With Conventional Assays in the Global Enteric Multicenter Study

    by Jordan Cates, Helen Powell, James Platts-Mills, Dilruba Nasrin, Sandra Panchalingam, Samba O Sow, Awa Traore, Dipika Sur, Thandavarayan Ramamurthy, Anita K M Zaidi, et al.

    Background: Quantitative molecular assays are increasingly used for detection of enteric viruses. Methods: We compared the clinical severity using the modified Vesikari score (mVS) of enteric viruses detected by conventional assays (enzyme immunoassays [EIAs] for rotavirus and adenovirus 40/41 and conventional polymerase chain reaction for astrovirus, sapovirus, and norovirus) and a quantitative molecular assay (TaqMan Array Card [TAC]) among children aged 0–59 months in the Global Enteric Multicenter Study. For rotavirus and adenovirus 40/41, we compared severity between EIA-positive and TAC-positive cases assigned etiologies using different cycle threshold (Ct) cutoffs. Results: Using conventional assays, the median mVS (interquartile range) was 10 (8–11) for rotavirus, 9 (7–11) for adenovirus 40/41, 8 (6–10) for astrovirus, sapovirus, and norovirus GII, and 7 (6–9) for norovirus GI. Compared with rotavirus EIA-positive cases, the median mVS was 2 and 3 points lower for EIA-negative/TAC-positive cases with Ct <32.6 or Ct ≥32.6 and <35, respectively (P < .001). Adenovirus 40/41 EIA-positive and EIA-negative/TAC-positive cases were similar, regardless of Ct cutoff. Conclusions: Quantitative molecular assays compared with conventional assays, such as EIA, may influence the severity of identified cases, especially for rotavirus. Cutoffs to assign etiology for quantitative assays should be considered in the design and interpretation of enteric virus studies.


  • Open Access

    Health Care Utilization and Clinical Management of All-Cause and Norovirus-Associated Acute Gastroenteritis Within a US Integrated Health Care System

    by Jordan Cates, Claire P Mattison, Holly Groom, Judy Donald, Rebecca P Hall, Mark A Schmidt, Aron J Hall, Allison L Naleway, Sara A Mirza

    Norovirus-associated acute gastroenteritis (AGE) exacts a substantial disease burden, yet the health care utilization for and clinical management of norovirus-associated AGE are not well characterized. We describe the health care encounters and therapeutics used for patients with all-cause and norovirus-associated AGE in the Kaiser Permanente Northwest health system from 1 April 2014 through 30 September 2016. Medical encounters for patients with AGE were extracted from electronic health records, and encounters within 30 days of one another were grouped into single episodes. An age-stratified random sample of patients completed surveys and provided stool samples for norovirus testing. In total, 40 348 individuals had 52 509 AGE episodes; 460 (14%) of 3310 participants in the substudy tested positive for norovirus. An overall 35% of all-cause AGE episodes and 29% of norovirus-associated AGE episodes had ≥2 encounters. While 80% of norovirus-associated AGE episodes had at least 1 encounter in the outpatient setting, all levels of the health care system were affected: 10%, 22%, 10%, and 2% of norovirus-associated AGE episodes had at least 1 encounter in virtual, urgent care, emergency department, and inpatient settings, respectively. Corresponding proportions of therapeutic use between norovirus-positive and norovirus-negative episodes were 13% and 10% for intravenous hydration (P = .07), 65% and 50% for oral rehydration (P < .001), 7% and 14% for empiric antibiotic therapy (P < .001), and 33% and 18% for antiemetics (P < .001). Increased health care utilization and therapeutics are likely needed for norovirus-associated AGE episodes during peak norovirus winter seasons, and these data illustrate that effective norovirus vaccines will likely result in less health care utilization.


  • Open Access

    Risk of Hospitalization and Mortality Following Medically Attended Norovirus Infection—Veterans Health Administration, 2010–2018

    by Jordan Cates, Cristina V Cardemil, Sara A Mirza, Ben Lopman, Aron J Hall, Mark Holodniy, Cynthia Lucero-Obusan

    While prior studies have suggested a role for norovirus gastroenteritis in contributing to severe morbidity and mortality, the importance of norovirus as a causal pathogen for hospitalization and mortality remains poorly understood. We estimated the effect of laboratory-confirmed norovirus infection on hospitalization and mortality among a national cohort of Veterans who sought care within the Veterans Affairs (VA) healthcare system. We analyzed electronic health record data from a cohort study of adults who were tested for norovirus within the VA between January 1, 2010—December 31, 2018. Adjusted risk ratios (aRRs) for hospitalization and mortality were estimated using log-binomial regression models, adjusting for age, Clostridioides difficile, underlying medical conditions, and nursing home residence. 23,196 Veterans had 25,668 stool samples tested for norovirus; 2,156 (8.4%) tested positive. Testing positive for norovirus infection, compared to testing negative, was associated with a slight increased risk of hospitalization (aRR: 1.13 [95% CI: 1.06, 1.21]) and a significant increased risk of mortality within three days after receiving a norovirus test (aRR: 2.14 [95% CI: 1.10, 4.14]). The mortality aRR within one week and one month reduced to 1.40 (95% CI: 0.84, 2.34) and 0.97 (95% CI: 0.70, 1.35), respectively. Older Veterans with multiple comorbidities were at a slight increased risk of hospitalization and significant increased risk of mortality in the three days after a norovirus-positive test compared with those testing negative. Clinicians should be aware of these risks and can use these data to inform clinical management for Veterans with norovirus.


  • Open Access

    Rotavirus Genotypes in the Postvaccine Era: A Systematic Review and Meta-analysis of Global, Regional, and Temporal Trends by Rotavirus Vaccine Introduction

    by Avnika B Amin, Jordan E Cates, Zihao Liu, Joanne Wu, Iman Ali, Alexia Rodriguez, Junaid Panjwani, Jacqueline E Tate, Benjamin A Lopman, Umesh D Parashar

    Background: Even moderate differences in rotavirus vaccine effectiveness against nonvaccine genotypes may exert selective pressures on circulating rotaviruses. Whether this vaccine effect or natural temporal fluctuations underlie observed changes in genotype distributions is unclear. Methods: We systematically reviewed studies reporting rotavirus genotypes from children <5 years of age globally between 2005 and 2023. We compared rotavirus genotypes between vaccine-introducing and nonintroducing settings globally and by World Health Organization (WHO) region, calendar time, and time since vaccine introduction. Results: Crude pooling of genotype data from 361 studies indicated higher G2P[4], a nonvaccine genotype, prevalence in vaccine-introducing settings, both globally and by WHO region. This difference did not emerge when examining genotypes over time in the Americas, the only region with robust longitudinal data. Relative to nonintroducing settings, G2P[4] detections were more likely in settings with recent introduction (eg, 1–2 years postintroduction adjusted odds ratio [aOR], 4.39; 95% confidence interval [CI], 2.87–6.72) but were similarly likely in settings with more time elapsed since introduction, (eg, 7 or more years aOR, 1.62; 95% CI, .49–5.37). Conclusions: When accounting for both regional and temporal trends, there was no substantial evidence of long-term vaccine-related selective pressures on circulating genotypes. Increased prevalence of G2P[4] may be transient after rotavirus vaccine introduction.


  • Open Access

    Risk Factors for Acute Gastroenteritis Among Patients Hospitalized in 5 Veterans Affairs Medical Centers, 2016–2019

    by Neha Balachandran, Jordan Cates, Anita K Kambhampati, Vincent C Marconi, Alexis Whitmire, Elena Morales, Sheldon T Brown, Diki Lama, Maria C Rodriguez-Barradas, Rosalba Gomez Moronez, et al.

    Background: In the United States, ∼179 million acute gastroenteritis (AGE) episodes occur annually. We aimed to identify risk factors for all-cause AGE, norovirus-associated vs non-norovirus AGE, and severe vs mild/moderate AGE among hospitalized adults. Methods: We enrolled 1029 AGE cases and 624 non-AGE controls from December 1, 2016, to November 30, 2019, at 5 Veterans Affairs Medical Centers. Patient interviews and medical chart abstractions were conducted, and participant stool samples were tested using the BioFire Gastrointestinal Panel. Severe AGE was defined as a modified Vesikari score of ≥11. Multivariate logistic regression was performed to assess associations between potential risk factors and outcomes; univariate analysis was conducted for norovirus-associated AGE due to limited sample size. Results: Among 1029 AGE cases, 551 (54%) had severe AGE and 44 (4%) were norovirus positive. Risk factors for all-cause AGE included immunosuppressive therapy (adjusted odds ratio [aOR], 5.6; 95% CI, 2.7–11.7), HIV infection (aOR, 3.9; 95% CI, 1.8–8.5), severe renal disease (aOR, 3.1; 95% CI, 1.8–5.2), and household contact with a person with AGE (aOR, 2.9; 95% CI, 1.3–6.7). Household (OR, 4.4; 95% CI, 1.6–12.0) and non-household contact (OR, 5.0; 95% CI, 2.2–11.5) with AGE was associated with norovirus-associated AGE. Norovirus positivity (aOR, 3.4; 95% CI, 1.3–8.8) was significantly associated with severe AGE. Conclusions: Patients with immunosuppressive therapy, HIV, and severe renal disease should be monitored for AGE and may benefit from targeted public health messaging regarding AGE prevention. These results may also direct future public health interventions, such as norovirus vaccines, to specific high-risk populations.


  • Open Access

    1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis

    by Jordan Cates, Avnika Amin, Jacqueline Tate, Ben Lopman, Umesh D Parashar

    Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 countries. Concerns exist that rotavirus vaccines may be less effective against rotavirus strains not contained in the vaccines which could subsequently cause selective pressure and strain replacement. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against vaccine (homotypic) and non-vaccine (partially and fully heterotypic) strains. After conducting a systematic review, we meta-analyzed 31 case-control studies (N=27,293) conducted between 2006 and 2020 using a random-effect regression model. In high-income countries, RV1 VE was 10% lower against partially heterotypic (p-value=0.04) and fully heterotypic (p-value=0.10) compared to homotypic strains (homotypic VE: 90% [95% CI: 82, 94]; partially heterotypic VE: 79% [95% CI: 71, 85]; fully heterotypic VE: 80% [95% CI: 65, 88]; Figure 1). In middle-income countries, RV1 VE was 14 to 16% lower against partially heterotypic (p-value=0.06) and fully heterotypic (p-value=0.04) compared to homotypic strains (homotypic VE: 81% [95% CI: 69, 88]; partially heterotypic VE: 67% [95% CI: 54, 76]; fully heterotypic VE: 65% [95% CI: 52, 75]; Figure 1). Strain-specific RV5 VE differences were less pronounced (Figure 2). Limited data were available from low-income countries. Figure 1. Vaccine effectiveness by country income level and strain type, for RV1. Figure 2. Vaccine effectiveness by country income level and strain type, for RV5. Vaccine effectiveness of RV1 and RV5 was somewhat lower VE against non-vaccine than vaccine strains. Ongoing surveillance is crucial to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited. All Authors: No reported disclosures